Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590326 · ClinicalTrials.gov registry record · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 612
- Enrollment target
- 20
- Study locations
NCT04590326: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Regeneron Pharmaceuticals.
NCT04590326 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 612 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590326, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 612 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2. The study is looking at several other research questions, including: * Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood * To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Primary Outcome
Dose escalation phase, Module 1
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG Ubamatamab
- DRUG REGN5668
- DRUG Sarilumab
- DRUG Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- The City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Chao Family Comprehensive Cancer Center - Orange
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute Brookline Avenue - Boston
Florida
- H. Lee Moffitt Cancer Center - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Pennsylvania
- Perelman School of Medicine at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 1 |
What NCT04590326 shows while recruiting
NCT04590326 is an interventional study that assigns participants to a tested intervention. The registered 612 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (16% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cemiplimab is the first listed.
NCT04590326 names 20 study sites across 16 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04590326 about?
NCT04590326 is a clinical study titled "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab". This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The mai...
What is the current status of trial NCT04590326?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 612 participants. The study started on 2020-12-08. Estimated completion is 2027-11-30.
What conditions does trial NCT04590326 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.
What interventions are being tested in trial NCT04590326?
The interventions under investigation include: Cemiplimab (DRUG), Ubamatamab (DRUG), REGN5668 (DRUG), Sarilumab (DRUG), Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] (DRUG).
Who is sponsoring clinical trial NCT04590326?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04590326 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04590326's enrollment target sits among peer trials
612 38th of 322 higher than 285 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT06266416 · 612 participants · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI